Abstract The purpose of the study was to evaluate the efficacy and safety of vitamin D 3 at 4000 IU/day as a treatment option for aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) when compared with the usual care dose of 600 IU D 3 . We conducted a single site randomized, double-blind, phase 3 clinical trial in women with AIMSS comparing change in symptoms, reproductive hormones and AI pharmacokinetics. Postmenopausal women C18 years with stages I-IIIA breast cancer, taking AI and experiencing AIMSS [breast cancer prevention trial symptom scale-musculoskeletal (BCPT-MS) subscale C1.5] were admitted. Following randomization, 116 patients had a run-in period of 1 month on 600 IU D 3 , then began the randomized assignment to either 600 IU D 3 (n = 56) or 4000 IU D 3 (n = 57) daily for 6 months. The primary endpoint was a change in AIMSS from baseline (after 1 month run-in) on the BCPT-MS (general MS pain, joint pain, muscle stiffness, range for each question: 0 = not at all to 4 = extremely). Groups had no statistically significant differences demographically or clinically. There were no discernable differences between the randomly allocated treatment groups at 6 months in measures of AIMSS, pharmacokinetics of anastrozole and letrozole, serum levels of reproductive hormones, or adverse events. We found no significant changes in AIMSS measures between women who took 4000 IU D 3 daily compared with 600 IU D 3 . The 4000 IU D 3 did not adversely affect reproductive hormone levels or the steady state pharmacokinetics of anastrozole or letrozole. In both groups, serum 25(OH)D remained in the recommended range for bone health (C30 ng/mL) and safety (\50 ng/ mL).
Introduction
Vitamin D 3 has emerged as a potential treatment for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) [1] [2] [3] [4] [5] [6] . AIMSS is characterized by a cluster of MS symptoms that include bone, muscle and joint pain, muscle stiffness, carpal tunnel syndrome, tenosynovitis, and allodynia [7] [8] [9] [10] [11] [12] [13] . These symptoms are also common in vitamin D deficiency [14, 15] .
Vitamin D (D) has a role in maintaining the integrity of the collagen-rich osteoid surface of the skeleton. In D insufficiency a demineralization of this matrix beneath the periosteum may contribute to pressure and pain [14, 16, 17] . The active hormone 1a,25-dihydroxyvitamin D 3 promotes muscle cell growth, which may lead to improved muscle function [18, 19] and a decrease in skeletal pain, thus providing biological rationale for the efficacy of D 3 in treating AIMSS. Supplemental vitamin D is prescribed for woman with AIMSS, often in doses exceeding the IOM and NCCN guidelines [20, 21] . However, caution is warranted with use of high-dose D 3 in oncology patients due to negative outcomes reported with dietary supplement use [22, 23] . Specific to D 3 , a U-shaped outcome response curve indicates a narrow range of serum 25(OH)D levels that correspond to good clinical outcomes [24] [25] [26] .
To inform clinical practice, we conducted a randomized, double-blind, controlled clinical trial in women with AIMSS, comparing the IOM tolerable upper intake levels (high-dose D 3 4000 IU/day) to the recommended dietary allowance (600 IU/day) as set by the Institute of Medicine [20] . Safety was assessed by examining the effects of D 3 on AI drug metabolism (letrozole and anastrozole) and on reproductive hormone levels.
Methods

Study design
This was a randomized, double-blind, single-site, phase 3 clinical trial conducted at Frauenshuh Cancer Center, a community-based oncology practice of Park Nicollet Health Services in Minneapolis, MN.
Study participants
The study was approved by the Institutional Review Boards at Park Nicollet Institute and the University of Minnesota. Informed consent was obtained before any study procedures.
Participants were enrolled between March 2012 and March 2014 and were randomly assigned (1:1) to the usual care dose of 600 IU D 3 or high dose of 4000 IU D 3 , plus 1000 mg calcium carbonate. Once enrolled, participants began a 4-week run-in period with 600 IU D 3 to allow serum levels to begin to normalize. After the run-in period, participants began in randomized groups and treatment duration was 6 months. Cholecalciferol (D 3 ) supplements were encapsulated and coded bottles prepared at Daily Manufacturing, Inc. (Rockwell, NC). Stability was tested at the beginning of the study and yearly thereafter. The unblinded biostatistician assigned coded bottles according to a blocked-randomization design in SAS v9.3 (2011, Cary, North Carolina). All study participants, their providers, and research staff remained blinded throughout the study.
The primary study endpoint was the change in MS symptoms between groups from baseline to 6 months. Secondary aims included an assessment of drug-nutrient interactions between D 3 and anastrozole and letrozole, AI adherence, and the effects of D 3 on reproductive hormone levels.
This study was open to post-menopausal women [18 years of age, with stages I-IIIA breast cancer, being treated with anastrozole, letrozole, or exemestane for at least 30 days and experiencing AIMSS at enrollment (prior to the run-in period). AIMSS were considered present and clinically significant if participants had a score of C1.5 on the breast cancer prevention symptom scales-MS subscale (BCPT-MS), regardless of temporal association with the start of AI therapy. This cut off of 1.5 was based on our previous study [27] . Patients were excluded if they had received previous AI treatment, had a history of rheumatoid arthritis, hypercalcemia or were taking excluded medications (see Fig. 1 ). Patients unwilling to discontinue other oral supplements containing D 3 and/or calcium were also excluded. Patients with osteoporosis were admitted if fracture risk was low as determined by a research rheumatologist, based on age, densitometry, and other bone mineral density-independent risk factors according to the WHO fracture risk assessment tool (FRAX) [28] .
Adherence
Adherence to assigned D 3 supplements was determined by pill counts at each in-person study visit. Medication adherence to AI was monitored through weekly diaries.
AIMSS measures
The BCPT-MS and the physical function subscales on the Australian/Canadian osteoarthritis hand index version 3.1 (AUSCAN) [29, 30] and the Western Ontario and McMaster osteoarthritis index version 3.1 (WOMAC) [31] are responsive to changes in AIMSS and the description and rationale for the use of these symptom scales in evaluating AIMSS interventions has been previously reported [27] . Higher scores on these measures represent worse symptoms. Measures of MS pain, both general and pain specific to hands, knees and hip joints, and physical functioning were collected at baseline and 6 months. Change in scores between baseline (following run-in with 600 IU D 3 ) and after 6 months was compared. Assessments included the BCPT-MS [27, 32] , the patient-reported outcomes measurement information system (PROMIS) physical functioning short form [33] (higher scores reflect better physical functioning), and the maximum handgrip strength test (HGST) on the dominant hand (lower scores represent worse symptoms) (Jamar hydraulic hand dynamometer, Sammons Preston Rolyan, Bolingbrook, IL) [34] . The AUSCAN and WOMAC were later added to the study schedule.
Biological measures
Serum 25(OH)D was measured by chemiluminescent immunoassay (Liaison/Liaison XL analyzer, DiaSorin, Stillwater, MN) at baseline and 6 months and safety assessments at 1.5 and 3 months. Park Nicollet Methodist Hospital Laboratory participates in CAP external proficiency testing. The lowest concentration that can be reported is 4 ng/mL. Assay imprecision (CVs) are 8.9 and 7.7 % at 15 and 50 ng/mL, with intra-assay precisions of 1.6 and 3.1 %, respectively, over the course of the study. The limit of detection is 1.9 pg/mL and CVs are 10.2, 7.6, and 5.5 % at 6, 10.9, and 24.9 pg/mL, respectively.
Pharmacokinetic studies were performed on plasma samples collected from heparinized tubes at baseline and 6 months and stored at -70°C until analyzed. Three samples were drawn from each patient at each occasion: fasting, then 2 and 4 h after AI dose. Steady state was assumed for all studies. The plasma concentrations of anastrozole and letrozole were determined using validated liquid chromatography tandem mass spectrometry methods [35] . The lower limits of quantitation were 0.05 ng/mL. Serum hormone levels were measured using available serum or plasma samples that were stored at -70°C until analyzed. Estrone, estradiol, and testosterone were quantified using organic solvent extraction and Celite column partition chromatography followed by radioimmunoassay [36, 37] . The assay sensitivities were 2 pg/mL for estrone, 1 pg/mL for estradiol and 15 pg/mL for testosterone. Sex hormone binding globulin was measured on an Immulite analyzer (Siemens Healthcare Diagnostics, Deerfield, IL) with a sensitivity of 1 nM. Free testosterone was calculated using a validated algorithm [38] [39] [40] . The intra-assay CVs range between 4.0 and 7.5 % for all the compounds, while the inter-assay CVs range between 8.0 and 13 %.
Analgesic use
The use of analgesics was recorded for each of the 7 days before AIMSS measures (baseline and 6-month visits). Analgesics were defined as any medication (including over-the-counter) or dietary supplements used to decrease any pain or discomfort in muscles or joints (e.g., NSAIDS, aspirin, prescription anti-inflammatory, opioid and nonopioid analgesics, glucosamine/chondroitin).
Sun exposure, exercise, and physical/occupational therapy Sun exposure was ascertained with questions modified from Glanz et al. [41] for exposure for 7 days before the baseline and 6-month visits, trips to sunny locations and the use of protective clothing and sunscreen over the 6-month study period. Participants reported exercise using the exercise questionnaire grid from the Harvard Nurses' Health Study II converted into weekly metabolic equivalent hours [42] for the month before the baseline and 6 months visits. Physical and occupational therapy (PT/ OT) visits at baseline and 6 months were verified via electronic medical records.
Sample size
Sample size calculations were based on a change in BCPT-MS score of 0.62. We have previously demonstrated that the BCPT-MS is sensitive to detect changes in AIMSS over a 6-month period and that a change of 0.62 in this symptom scale represents a clinically significant change [27] . Assuming a two-tailed test with a = 0.05, power = 80 %, and standard deviation of 1.18, sample size of 116 (58 per group) would detect a difference of 0.62 in mean scores (moderate effect size of 0.525).
Statistical analyses
All statistical analyses were intent-to-treat using SAS v9.3 (2011, Cary, North Carolina). Baseline characteristics were compared between groups using independent t-tests for continuous variables and v 2 for categorical variables. For variables that were not normally distributed, log transformations were successfully used to achieve normality in the analyses.
Analysis of covariance (ANCOVA) was used to determine if the change in AIMSS from baseline to 6 months differed between the two groups. The 6-month AIMSS scores were the dependent variables. Independent variables used in the models were group assignment and baseline AIMSS scores. Covariates that affect AIMSS were entered into the models and included months on AI (\6/ C6 months), chemotherapy (y/n), taxane use (y/n), MS comorbidities (y/n), medications that affect AIMSS (statins, NSAIDS, SSRIs, pain medications), and season of blood draws (Spring-Summer April 1st-September 30th or Fall-Winter October 1st-March 31st). Interactions of these covariates, sun exposure, exercise, and PT/OT utilization with treatment group were assessed but no interactions were found, and they were not included in the final model.
A one-compartment model was fitted to the plasma concentration-time profiles of anastrozole and letrozole by means of nonlinear mixed-effects modeling using NON-MEM 7.2 (ICON Development Solutions, Ellicott City, MD, USA). Steady state concentrations (Css) of anastrozole and letrozole were calculated by the following equation: Css = dose/(dosing interval * CL/F individual ) [43] .
Vitamin D 3 dose, serum total, and free 25(OH)D concentrations were tested as covariates on AI Css, and the statistical significance was determined by the likelihood ratio test (LRT).
Hormone determinations were reported as geometric means with 95 % confidence intervals. Additionally, hormone levels at 6 months were log transformed and analyzed using ANCOVA, with baseline level as a covariate.
We conducted secondary analyses to explore associations between 25(OH)D levels (both total and free), BCPT-MS scores, and estradiol levels within each treatment group using Pearson correlation coefficients.
Results
There were 906 patients on AIs assessed for study eligibility. Of those screened, 426 (47 %) had MS symptoms (BCPT-MS score C1.5) and 116 patients were randomly assigned to either the usual care group receiving 600 IU D 3 /day plus 1000 mg calcium (n = 59) or the high-dose group receiving 4000 IU D 3 /day plus 1000 mg calcium (n = 57; Fig. 1 ).
Patient demographics and disease characteristics were not statistically different between groups (Table 1) . At baseline, 55 (48 %) patients were taking letrozole, 47 (41 %) were taking anastrozole, and 11 (9 %) were taking exemestane. Patients had been on AI treatment for 19.9 ± 17.0 months (mean ± SD), and 54 % (n = 61) of patients had received prior chemotherapy, completed more than 33 months before enrollment. Among all study patients, 32 % had prior taxane as part of their treatment, and this did not differ between groups. Approximately 43 % (n = 49) of participants enrolled had MS comorbidities at study entry. There were no differences between groups on any of the baseline AIMSS measures.
Medication adherence for AIs was [97 % over the course of the study and adherence to the vitamin D intervention was [95 % at each study time point.
After the run-in period, the mean baseline serum total 25(OH)D level for all participants was 36.6 ± 13.0 ng/mL (mean ± SD), and free serum 25(OH)D was 8.0 ± 3.2 pg/ mL (mean ± SD). Five participants in the high-dose group and four participants in the usual care group had insufficient 25(OH)D levels of B20 ng/mL and no participants were vitamin D deficient. At 6 months, all participants were vitamin D sufficient. Table 2 and Fig. 2 show the serum 25(OH)D concentrations by group. After 6 months of supplementation, there was a statistically significant difference in the change in serum 25(OH)D between groups (a decrease of 2.6 ± 7.6 ng/mL in usual care vs. an increase of 9.3 ± 10.4 in the high-dose group; p \ 0.0001). In the high-dose group, serum levels of both total and free 25(OH)D increased from baseline to 6 months (total: 37.0 ± 14 to 46.3 ± 11 ng/mL, p \ 0.0001, free: 8.1 ± 3.9 to 11.2 ± 3.2 pg/mL, p \ 0.0001). In the usual care group, total 25(OH)D levels decreased at 6 months, from 36.4 ± 12.1 ng/mL at baseline to 33.7 ± 8.7 at 6 months; p \ 0.02. Sun exposure and exercise did not differ between groups and thus did not affect 25(OH)D levels. Table 3 summarizes the AIMSS measures by group, for participants who had both baseline and 6-month measurements. Following the run-in period, BCPT-MS scores were similar in both groups (2.4 ± 0.7 in usual care group vs. p-Value for differences between groups from GLM Total vitamin D for difference from baseline to 6 months for control group, p = 0.0141, for experimental group, p = \0.0001
Free vitamin D for difference from baseline to 6 months for control group, p = 0.0155, for experimental group, p = \0.0001 2.3 ± 0.6 in the high-dose group; mean ± SD). After 6 months in the assigned groups, there were no statistically significant differences in the change in BCPT-MS scores between groups (change of -0.5 ± 0.9 in usual care group vs. -0.2 ± 0.7 in the high-dose group; p [ 0.37 for differences between groups). The subscales for pain, stiffness, and physical function on the AUSCAN, WOMAC, PRO-MIS, and the HGST did not show any differences between groups for the change from baseline to 6 months. There were no differences in exercise or PT/OT utilization between groups and these did not affect AIMSS measures. Secondary, exploratory analyses within each group did not show clinically significant correlations between free or total serum 25(OH)D and BCPT-MS scores, hand-grip strength or estradiol concentrations. Figure 3 shows the Css of anastrozole and letrozole in individual patients by group at baseline and 6 months. Css for exemestane were not assayed. The high-dose vitamin D 3 did not affect Css (LRT, p = 0.1). Neither serum total nor free 25(OH)D was significantly associated with Css (p = 0.16).
There were no significant differences in the change in reproductive hormone concentrations for estrone, estradiol, testosterone (free and total), and sex-hormone binding globulin between groups from baseline to 6 months ( Table 4) .
The most frequent adverse events according to CTCAE v. 4.0 were MS (18 %) and gastrointestinal (17 %) in nature and these did not differ between groups.
Discussion
This randomized trial comparing a high dose of 4000 IU D 3 to the usual care dose of 600 IU found no difference in MS symptoms after 6 months. This was observed in the setting of a significant change in both total and free serum 25(OH)D levels (decrease in usual care group and increase in high-dose group). There was no effect of vitamin D 3 supplementation on AI clearance (drug/nutrient interaction) or on reproductive hormone levels.
Our findings differ from other trials on vitamin D and AIMSS. A randomized trial in 147 women initiating letrozole treatment observed a higher proportion of MS events in women taking 600 IU D 3 plus calcium compared with those given an additional single weekly dose of 30,000 IU D 3 for 6 months (p \ 0.008). This study compared AIMSS measures taken before AI initiation to those following 6 months of supplementation [1] . A smaller, single-arm pilot study (n = 60) found less joint pain and joint disability in women who achieved serum levels of 25(OH)D [66 ng/mL with D 3 supplementation for 12 weeks [5] . Because baseline 25(OH)D levels in both of these trials were measured before D supplementation, serum levels were lower than in our study in which baseline values reflect 4-week run-in on 600 IU D 3 . This might contribute to the discrepancy in our results.
Rastelli et al. [2] conducted a small randomized trial in 60 women with 25(OH)D \30 ng/mL who were experiencing AIMSS while on anastrozole. Patients were Hand grip measured in pounds is maximum strength on dominant hand p Value for change in BCPT-MS within group: control group, p = 0.0004 for baseline-6 months; experimental group, p = 0.01 for baseline-6 months. p Value for change in WOMAC physical function within group: experimental group, p = 0.02 for baseline-6 months.
* p Values for between-group differences are from ANCOVA, controlling for musculoskeletal comorbidities (y/n), months on AI (\6/ C6 months), on meds that affect AIMSS (y/n), taxane use (y/n), season, and had chemotherapy (y/n) Breast Cancer Res Treat (2016) 155:501-512 507 stratified according to their baseline 25(OH)D and all received 400 IU D 3 plus calcium and an additional dose of 50,000 IU of ergocalciferol (D 2 ) weekly or monthly for 8 or 16 weeks, depending on their serum levels. There was a significant decrease in self-reported pain after 2 months; however, this decrease in pain was not sustained at 4 or 6 months. Others have suggested that there is a threshold for 25(OH)D levels to achieve positive effects of D 3 on AIMSS. An improvement in joint pain has been reported in women on AIs when serum 25(OH)D levels of C40 ng/mL were achieved [3, 4] . In our study, the high-dose vitamin D group achieved a mean total 25(OH)D concentration of 46.3 ± 11 ng/mL at 6 months with no observed differences in AIMSS.
Similar to our findings, a prospective study found no association between of 25(OH)D levels and AIMSS in women initiating AI when compared with a cancer-free group [44] . Similarly, the IBIS-II cancer prevention trial also reported that low serum levels of 25(OH)D did not predict AIMSS in postmenopausal women taking anastrozole [45] . Hand disability and hand-grip strength are reported to be associated with tenosynovial changes in the hands and wrist in women on AIs [12, 46] and hand disability is seen in the general population with low 25(OH)D levels [47] . After 6 months of supplementation, we found no differences in changes in hand disability or hand strength between groups.
While a supplemental dose of vitamin D 3 of 4000 IU/day is the safe upper limit [20] , in vitro studies indicate that the active form, 1a,25(OH)D 3 can affect reproductive hormone levels in a tissue-specific manner [48] [49] [50] [51] [52] [53] and in patients on AIs, serum estradiol has been positively associated with 25(OH)D levels [54] . Here we report that 4000 IU D 3 did not abrogate the estrogen-suppressing action of AIs nor the steady state levels of anastrozole or letrozole.
Research continues into identifying risk factors and strategies to manage AIMSS symptoms. Patients and their physicians often treat AIMSS with non-steroidal anti-inflammatory medication and acetaminophen, with antidepressant and anticonvulsants as with other chronic pain disorders, various other over-the counter supplements, as well as non-pharmacologic approaches. Recently studied approaches include exercise [55] , Tai Chi [56] , yoga [57] , and glucosamine with chondroitin [58] . Acupuncture has demonstrated efficacy in some but not all studies [59] [60] [61] . Others have failed to find significant benefit from omega-3 fatty acids [62] . Other strategies include switching AIs [63] , or treatment of underlying and potentially exacerbating factors such as insomnia and fear of recurrence [64, 65] . Some approaches currently under investigation include duloxetine (SWOG#S1202) and traditional Chinese medicines [66] .
This study has several strengths. First, the BCPT-MS has a low respondent burden and we previously demonstrated the ability of the BCPT-MS to identify and measure AIMSS prospectively [27] . Second, we accounted for effect modifiers that can influence AIMSS and 25(OH)D: percent body fat, sun exposure, exercise, bisphosphonate use, years since menopause, prior taxane exposure, preexisting MS co-morbidities, PT/OT, and medications that can affect both arthralgia and/or vitamin D levels. These did not differ between groups at baseline or after 6 months and therefore do not account for our results. Third, to our knowledge, this is the first report of the relationship of free, bioavailable 25(OH)D with AIMSS, thus eliminating the possible variation in vitamin D-binding protein [67] . Finally, while there is little data from controlled trials to support exceeding the current recommendations of 600 IU D 3 /day for those aged 1-70 years or [800 IU for those older than 71 years, research does support C800 IU to prevent fractures for those older than 65 [49, 68] . Our findings support recommendations that women on AI might be advised to take a daily supplement 600-800 IU D 3 daily, which appears safe and would support bone health.
This study has limitations. The run-in period was designed to accommodate the prevailing use of D supplementation in women on AIs [69] . It is possible that vitamin D has a role in altering AIMSS in women with low 25(OH)D (\30 ng/mL). Although our data cannot address this due to the run-in period, D insufficiency does not currently appear as prevalent in this population. Previous reports of D insufficiency [70, 71] have resulted in a high rate of D 3 use among breast cancer survivors [69] .
Second, higher doses of D 3 may yield different results but caution is warranted. The correlation between serum 25(OH)D levels and outcomes appears to have a U or J shaped relationship, suggesting benefit at the middle range of serum 25(OH)D levels and negative health outcomes at both lower and higher levels [24, 72] . Third, this was a single site study with 93 % of the participants Caucasian, limiting the generalizability of the findings.
In summary, we found no significant changes in AIMSS measures between women who took 4000 IU D 3 daily compared with 600 IU D 3 . However, we did not document any harm from vitamin D supplementation in this study; the high-dose vitamin D 3 used in this study did not adversely affect reproductive hormone levels or the steady state pharmacokinetics of anastrozole or letrozole. In both groups, serum 25(OH)D remained in the recommended range for bone health (C30 ng/mL) [68] and safety (\50 ng/mL) [20] . 
